UVADEX Drug Patent Profile
✉ Email this page to a colleague
When do Uvadex patents expire, and what generic alternatives are available?
Uvadex is a drug marketed by Mallinckrodt Hosp and is included in one NDA.
The generic ingredient in UVADEX is methoxsalen. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methoxsalen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Uvadex
A generic version of UVADEX was approved as methoxsalen by STRIDES PHARMA on June 5th, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for UVADEX?
- What are the global sales for UVADEX?
- What is Average Wholesale Price for UVADEX?
Summary for UVADEX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 150 |
Clinical Trials: | 17 |
Patent Applications: | 5,091 |
Drug Prices: | Drug price information for UVADEX |
What excipients (inactive ingredients) are in UVADEX? | UVADEX excipients list |
DailyMed Link: | UVADEX at DailyMed |
Recent Clinical Trials for UVADEX
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Central Hospital, Nancy, France | Phase 2 |
Lawson Health Research Institute | Phase 2 |
European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
Pharmacology for UVADEX
Drug Class | Photoactivated Radical Generator Psoralen |
Mechanism of Action | Photoabsorption |
Physiological Effect | Photosensitizing Activity |
US Patents and Regulatory Information for UVADEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mallinckrodt Hosp | UVADEX | methoxsalen | INJECTABLE;INJECTION | 020969-001 | Feb 25, 1999 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for UVADEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Mallinckrodt Hosp | UVADEX | methoxsalen | INJECTABLE;INJECTION | 020969-001 | Feb 25, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Mallinckrodt Hosp | UVADEX | methoxsalen | INJECTABLE;INJECTION | 020969-001 | Feb 25, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Mallinckrodt Hosp | UVADEX | methoxsalen | INJECTABLE;INJECTION | 020969-001 | Feb 25, 1999 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for UVADEX
See the table below for patents covering UVADEX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Germany | 3586960 | ⤷ Sign Up | |
Japan | 2837407 | ⤷ Sign Up | |
Japan | S62278 | DEVELOPMENT OF BIOLOGICALLY ACTIVE PDGF ANALOGUE FACTOR IN EUKARYOTIC CELL | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for UVADEX
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0177957 | C990016 | Netherlands | ⤷ Sign Up | PRODUCT NAME: BECAPLERMINUM; REGISTRATION NO/DATE: EU/1/99/101/001 19990329 |
0177957 | 99C0034 | Belgium | ⤷ Sign Up | PRODUCT NAME: BECAPLERMIN; REGISTRATION NO/DATE: EU/1/99/101/001 19990329 |
0177957 | SPC/GB99/023 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: BECAPLERMIN; REGISTERED: UK EU/1/99/101/001 19990329 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |